Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

In a phase 2 trial (CTRI/2023/07/055785), ado-trastuzumab emtansine (T-DM1; Kadcyla) was well-tolerated in HER2-positive biliary tract adenocarcinoma, but it did not show a statistically significant ...

Get Instant Summarized Text (Gist) The FDA has approved Enhertu for treating adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval follows the ...

1 Frequency of emesis in the absence of effective antiemetic prophylaxis. 2 May be highly emetogenic in certain patients. 3 Routine premedication may not be required. An individualized approach is ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial. In patients with HER2 ...

Explore See latest videos, charts and news Ado YOASOBI See latest videos, charts and news Scheduled to take place March 16, 2025, at the Peacock Theater in Los Angeles, California, the event will ...

Recent trials demonstrated that adjuvant trastuzumab emtansine (T-DM1) had some improved outcomes compared to trastuzumab in early analysis. This study reported an updated final analysis of adjuvant T ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

ado-trastuzumab emtansine, trastuzumab deruxtecan, tucatinib, and neratinib. Patients responded to margetuximab plus chemotherapy with real-world progression-free survival (PFS) of 3, 4, and 7 months.